The global antithrombotic drugs market was valued at $26557.86 million in 2018 & is estimated to generate net revenue of approximately $47953.42 million by 2027, growing at a CAGR of 6.79%. Antiplatelet, anticoagulant, and thrombolytic agents are different types of antithrombotic agents that act through different clotting processes.

The following factors primarily drive the antithrombotic drugs market:

• Growing demand for NOACS
• The surge in hip and knee replacement surgeries
• Healthcare policies and programs by government
• Growing aging population

To know more about this report, request a free sample copy.

The important drivers increasing growth in the global antithrombotic drugs market are increasing demand for NOACS and healthcare policies and programs by the government. The increasing adoption rates of NOACs are driving the market growth. NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. The governments of the various regions are taking initiatives to make the country healthy.

Antithrombotic drugs are used extensively for various health treatments. Anticoagulants, also referred to as blood-thinning agents are drugs that prevent clot formation and help in the free flow of blood in the body. The Anticoagulants by drug type is segmented into Low Molecular Weight Heparin and Oral Anticoagulants (vitamin K antagonists). The anticoagulant by ROA has been divided into Oral and Injectables. Several agents alter coagulation through their ability to inhibit the aggregation of platelets. Aspirin’s antiplatelet action results in the decrease of the synthesis of endoperoxides and thromboxanes, which are substances that mediate platelet aggregation. Antithrombin agents act by reversibly binding to an active thrombin site or both the catalytic and anion- binding exosite of thrombin, inhibiting the effects of thrombin. Betrixaban (INN, code-named PRT-054021) is an anticoagulant drug that acts as a direct factor Xa inhibitor. Angiomax (bivalirudin), offered by The Medicines Co., is used for its anticoagulant properties on patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.

The high cost of NOACS and lack of resources in underdeveloped countries are the major factors hindering the antithrombotic drugs market. The cost of NOACs that are available in the market is higher than the conventional drugs such as Warfarin. The average price of generic warfarin for a months’ supply is more than the traditional drugs. Lack of financial resources, inadequate income, and ignorance about health conditions hinder the antithrombotic market growth in underdeveloped countries of Asia and Africa.

The global antithrombotic drugs market segments include antithrombotic drugs types.

Antithrombotic Drugs types are segmented into:

• Market by antithrombotic drugs types
  • Anticoagulants
    • Anticoagulants by drugs type
      • Low Molecular Weight Heparin
      • Oral anticoagulants (vitamin k antagonists)
    • Anticoagulants by Rapid Onset Anticoagulant (ROA)
      • Oral
      • Injectables
    • Anticoagulants by drug class
      • Factor XA
      • DTIS
      • Heparin
      • Vitamin K antagonists
    • Anticoagulants by applications
      • PE
      • DVT
      • AF
      • Other anticoagulants applications
  • Antiplatelets
    • Oral antiplatelets
    • IV antiplatelets
  • Thrombin inhibitors
    • Direct factor XA inhibitors
    • Direct thrombin inhibitors
    • Thrombolytic agents

This report covers the present market conditions and the growth prospects of the global antithrombotic drugs market for 2019-2027 and considered the revenue generated through the sales of antithrombotic drugs. The base year considered is 2018 to calculate the market size.

Geographically, the global Antithrombotic drugs market has been segmented into four major regions, which include:

• North America: The United States & Canada
• Asia Pacific: China, India, Japan, South Korea, Australia, and Rest of APAC
• Europe: The United Kingdom, France, Germany, Spain, Italy, and Rest of Europe
• Rest of World: Latin America & Middle East and Africa

The antithrombotic drugs market in North America is expected to hold the largest share by 2027 and the possibilities of growing at a significant pace with the introduction of NOACs. North America constitutes a market share of approx. 38% during the forecast period. The warfarin showed high growth when compared with an oral anticoagulant. However, the revenue generated from the sales of warfarin is low due to the availability of generics, which are available at prices that are 15-20 times lower than that of NOACs. Anticoagulants are among the most frequently prescribed drugs in the United States. On the other hand, the Asia Pacific market is anticipated to the fastest-growing region for the antithrombotic drugs market. APAC is expected to increase at a fast pace when compared with Europe and the Americas owing to the low awareness. With the increasing awareness and improving healthcare infrastructure, the patient pool should increase in APAC.

The major market players in the global antithrombotic drugs market are:

• ABBOT LABORATORIES
• BAYER
• ARMETHEON INC.
• ELI LILLY AND COMPANY
• BOEHRINGER INGELHEIM GMBH

Company Profiles covers the analysis of important players.

Abbott Laboratories (Abbott or ‘the company’) is a diversified healthcare company with a portfolio diagnostic products, medical devices, nutritionals and branded generic pharmaceuticals. The company markets its products in several countries, with major operations in the US, the Netherlands, Germany, Japan, Italy, France, Canada, the UK, and Spain. Eli Lilly and Company, is a pharmaceutical company based in Indiana, US, and was founded in 1876 by Eli Lilly. Eli Lilly and Company has its presence in the Americas, Asia Pacific, Africa, and Europe.

Key findings of the global antithrombotic drugs market:

• Anticoagulants generate the highest revenue in the antithrombotic market
• Oral antiplatelets are widely used
• Direct factor XA inhibitors are anticipated to grow significantly during the forecast period